Northwest Oncology LLC

Futó vizsgálatok

• Toboroz

  Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  NCT07388524· 3. fázis· Forrás

• Toboroz

  Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

  NCT07283939· Forrás

• Toboroz

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· 3. fázis· Forrás

• Toboroz

  Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  NCT06649812· 2. fázis· Forrás

• Toboroz

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· 3. fázis· Forrás

• Toboroz

  Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  NCT06616584· 2/3. fázis· Forrás

• Toboroz

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· 3. fázis· Forrás

• Fut, nem toboroz

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· 3. fázis· Forrás

• Toboroz

  Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  NCT06116682· 2. fázis· Forrás

• Toboroz

  Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

  NCT06337318· 3. fázis· Forrás

• Fut, nem toboroz

  The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

  NCT06115499· 2/3. fázis· Forrás

• Toboroz

  Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  NCT06031688· 2. fázis· Forrás

• Toboroz

  Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  NCT06096844· 3. fázis· Forrás

• Toboroz

  Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

  NCT06205485· 3. fázis· Forrás

• Toboroz

  Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  NCT06203600· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

  NCT05836584· 2. fázis· Forrás

• Toboroz

  Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

  NCT05976763· 3. fázis· Forrás

• Toboroz

  Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  NCT05561387· 3. fázis· Forrás

• Toboroz

  Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  NCT05890352· 2. fázis· Forrás

• Toboroz

  Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  NCT05929768· 3. fázis· Forrás

• Fut, nem toboroz

  Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

  NCT05710406· 2/3. fázis· Forrás

• Toboroz

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· 3. fázis· Forrás

• Toboroz

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· 3. fázis· Forrás

• Fut, nem toboroz

  Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

  NCT05633602· 3. fázis· Forrás

• Toboroz

  mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  NCT05677490· 3. fázis· Forrás

• Fut, nem toboroz

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

  NCT05256225· 3. fázis· Forrás

• Fut, nem toboroz

  Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

  NCT05308446· 2. fázis· Forrás

• Toboroz

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

  NCT05092958· 3. fázis· Forrás

• Toboroz

  Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  NCT05112601· 2. fázis· Forrás

• Fut, nem toboroz

  Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

  NCT05095376· 3. fázis· Forrás

• Toboroz

  Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

  NCT05080673· Forrás

• Toboroz

  APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  NCT04858334· 2. fázis· Forrás

• Toboroz

  Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  NCT04181060· 3. fázis· Forrás

• Fut, nem toboroz

  Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

  NCT04233866· 2. fázis· Forrás

• Fut, nem toboroz

  Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

  NCT04137107· 2/3. fázis· Forrás

• Toboroz

  Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  NCT04267848· 3. fázis· Forrás

• Fut, nem toboroz

  S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

  NCT04155034· 3. fázis· Forrás

• Fut, nem toboroz

  Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

  NCT04068103· 2/3. fázis· Forrás

• Fut, nem toboroz

  Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688· 3. fázis· Forrás

• Fut, nem toboroz

  Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

  NCT03914612· 3. fázis· Forrás

• Toboroz

  Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

  NCT03660826· 2. fázis· Forrás

• Fut, nem toboroz

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· 3. fázis· Forrás

• Fut, nem toboroz

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák9 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Vastagbélrák3 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)2 toboroz
• Follikuláris limfóma2 toboroz
• Gyermekkori daganatok2 toboroz
• Hasnyálmirigyrák2 toboroz
• Tripla negatív emlőrák2 toboroz
• Köpenysejtes limfóma1 toboroz
• Méhnyakrák1 toboroz
• Méhtestrák1 toboroz
• Mielóma multiplex1 toboroz
• Petefészekrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Leállították

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· 3. fázis· Forrás